Cyamemazine is an antipsychotic compound with sedative and anxiolytic activity. Cyamemazine is a 5-HT3, 5-HT2A, and 5-HT2C receptor antagonist with Ki values of 12 nM, 1.5 nM, and 75 nM, respectively.

5-HT2C Receptor:12 nM （Ki）, 5-HT2A Receptor:1.5 nM （Ki）, 5-HT3 Receptor:75 nM （Ki）

METHODS: The antagonistic effects of Cyamemazine on various receptors, such as D2, 5-HT2A, 5-HT2C, and 5-HT3 receptors, were determined through binding experiments.
RESULTS: Cyamemazine showed strong antagonistic effects on D2 and 5-HT2A receptors, and relatively weaker antagonistic effects on 5-HT2C and 5-HT3 receptors. This receptor activity is associated with its anxiolytic effects [1].

METHODS: The Elevated Plus Maze (EPM) test was conducted in mice to evaluate the anxiolytic-like behavior of Cyamemazine under acute and chronic dosing conditions.
RESULTS: In the acute dosing condition, Cyamemazine exhibited anxiolytic-like activity in the light/dark exploration test. In the chronic dosing condition, it increased the time spent in the open arms of the Elevated Plus Maze, demonstrating its anxiolytic effects [1].